WHO Advances Uganda–DRC Cross-Border Ebola Health Roadmap as US HHS Closes Comment Period on Islet Cell Transplant Reform
The WHO Regional Office for Africa reported on November 9 that Uganda and the Democratic Republic of the Congo agreed in Kampala on an accelerated cross-border health security roadmap after deploying three Ebola treatment units and three mobile labs that completed over 5,000 tests, while the US Department of Health and Human Services concluded public comment on shifting unmodified donor islet cells from FDA biologics rules to the HRSA/OPTN organ transplant framework.
By 全球伯乐 News
Research and compilation
On this page
Over 5,000 Diagnostic Tests Across Three Mobile Labs: Uganda and DRC Seal Kampala Health Security Roadmap
On November 9, 2026, the World Health Organization (WHO) Regional Office for Africa announced from Kampala that the governments of Uganda and the Democratic Republic of the Congo (DRC) have agreed on an operational roadmap to accelerate their June 2026 cross-border health security Memorandum of Understanding (MoU), following a high-level bilateral meeting convened by WHO Regional Director for Africa Dr Mohamed Yakub Janabi1. With communities and traders moving daily across their shared border, the Kampala accord establishes multi-tier coordination structures spanning national, provincial, district, and community levels to combat Ebola disease and other epidemic-prone pathogens1.

AI-generated editorial illustration: a clear glass dish containing three amber cellular cluster models on a flat natural stone slab flanked by a dark-green stethoscope, a kraft folder and a wooden-handled magnifying glass represent cross-border epidemic surveillance and islet cell transplantation regulatory review, not clinical specimens.
Field figures released at the Kampala meeting demonstrate tangible clinical and diagnostic capacity built since June 2026: Uganda has supported the establishment of three Ebola treatment units in the DRC health zones of Aru, Chomia, and Butembo, with a fourth facility currently under construction, while deploying three mobile laboratories to the DRC that have performed more than 5,000 diagnostic tests over the past three months1. Ugandan Minister of Health Dr Chris Baryomunsi and DRC National Incident Manager and Presidential Taskforce Chair Prof Steve Ahuka confirmed that the two nations will institutionalize routine epidemiological data exchange, joint surveillance at points of entry, and collaborative evaluation of novel diagnostics and medical countermeasures1.
Reclassifying Islet Cells from FDA Biologics to HRSA/OPTN Organ Transplants: US HHS Wraps Up Public Consultation
Alongside cross-border infectious disease coordination in East Africa, US biomedical regulators reached a key milestone in reviewing patient access to cellular therapies for chronic metabolic disease. On November 8, 2026, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) closed the formal public comment window on their Request for Information (RFI), 'Improving Patient Access to Deceased Donor Islet Cells and Cell Products' (Docket No. FDA-2026-N-10738)2. The initiative evaluates whether regulating deceased donor pancreatic islet cells under the FDA's biological product framework creates unnecessary barriers for patients with type 1 diabetes2.
Pancreatic islet clusters contain insulin-producing beta cells that, when isolated from a deceased donor pancreas and infused into a recipient, can restore endogenous insulin production and reduce or eliminate the need for daily insulin injections2. Specifically, the HHS inquiry examines whether 'unmodified' deceased donor islet cells should be reclassified as human organs for transplantation rather than biological drug products—a shift that would transfer oversight of procurement, national waiting list allocation, and transplantation from the FDA to the Health Resources and Services Administration (HRSA) and the Organ Procurement and Transplantation Network (OPTN) while preserving patient safety standards2. Both the Kampala cross-border health pact and the HHS islet cell regulatory review illustrate how health authorities are redesigning institutional frameworks to speed the delivery of life-saving diagnostics and cellular therapies12.
Source notes
-
2026-11-09 · Uganda and the Democratic Republic of the Congo strengthen cross-border collaboration on health security · World Health Organization (WHO) Regional Office for Africa. ↩ ↩2 ↩3 ↩4 ↩5
-
2026-09-23 · HHS Seeks Public Input to Improve Access to Deceased Donor Islet Cell Treatments · U.S. Department of Health and Human Services (HHS). ↩ ↩2 ↩3 ↩4 ↩5


